SEMINARS IN ARTHRITIS AND RHEUMATISM, cilt.48, sa.3, ss.467-474, 2018 (SCI-Expanded)
Background: Low disease activity is a validated target of current systemic lupus erythematosus (SLE) therapy. The aim of this study was to assess the ability of belimumab to achieve low disease activity states in real-life settings.